Click here for slides on this topic


Atorvastatin

A drug in the statin (HMG-CoA reductase inhibitor) class that is indicated to treat high cholesterol as an adjunct to diet, and to reduce cardiovascular disease.
The following content matched the glossary term: Atorvastatin

Clinical Insights in Diabetes Newsletter October 2013

Top

Clinical Insights® in Diabetes newsletter October 2013

Exploring DPP-4 CV safety in SAVOR-TIMI 53 and EXAMINE, CV outcomes in Look AHEAD, relationship between gastric bypass and A1C and cardiometabolic risk factors, metabolic effects of bariatric surgery and medical therapy in STAMPEDE, statin use and diabetes risk, severe hypoglycemia and CVD disease risk.

Risk of incident diabetes among patients treated with statins: population based study

Top

Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013;346:f2610 doi:10.1136/bmj.f2610.

Statins and new-onset diabetes: a retrospective longitudinal cohort study

Top

Ma T, Tien L, Fang CL, Liou YS, Jong GP. Statins and new onset diabetes a retrospective longitudinal cohort study. Clin Ther. 2012;34(9):1977-1983. Statins have been linked to new-onset diabetes (NOD); however, the effect of statins on the development of NOD in patients with hypertension and dyslipidemia has not been well studied.

NDEI.org Expert Commentary Statins and Gender Peter Ganz

Top

Expert commentary on statins and gender from Peter Ganz, MD.

Clinical Insights in Diabetes Newsletter Archive

Top

Clinical Insights® in Diabetes Newsletter Archive

Effects of torcetrapib in patients at high risk for coronary events

Top

Barter PJ, Caulfield M, Eriksson M, et al; for the ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109-22. Inhibition of cholesteryl ester transfer protein (CETP) has been shown to have a substantial effect on plasma lipoprotein levels. We investigated whether torcetrapib, a potent CETP inhibitor, might reduce major cardiovascular events.

Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial

Top

Ahmed S, Cannon CP, Murphy SA, Braunwald E. Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial. Eur Heart J. 2006;27:2323-2329. The impact of intensive lipid lowering therapy with statins in acute coronary syndrome (ACS) patients with diabetes mellitus (DM) is not well characterized.

High-dose atorvastatin after stroke or transient ischemic attack

Top

Amarenco P, Bogousslavsky J, Callahan A 3rd, et al for the SPARCL Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-559. Statins reduce the incidence of strokes among patients at increased risk for cardiovascular disease; whether they reduce the risk of stroke after a recent stroke or transient ischemic attack (TIA) remains to be established.

Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus

Top

Croom KF, Plosker GL. Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus. Drugs. 2005;65:137-152. Atorvastatin is an HMG-CoA reductase inhibitor with well documented lipid-lowering effects.

1 2 Next 

Slide Library Results

Search Results for: Atorvastatin Slides Found: 27
ACP Guidelines on Management of Dyslipidemia in Type 2 Diabetes
Results From Statin Trials for Patients With Diabetes
SPARCL: Primary Outcome of Fatal or Nonfatal Stroke
SPARCL: First Events
TNT: Intensive Atorvastatin Treatment Reduces Cardiovascular Events in Patients With CHD and Diabetes
Meta-Analysis: Risk for New-Onset Diabetes and CV Events with Intensive- Vs Moderate Dose Statins
Meta-Analysis: New-Onset Diabetes and CV Events With Intensive- Vs Moderate-Dose Statins
Meta-Analysis: New-Onset Diabetes With Intensive- Vs Moderate-Dose Statins
Meta-Analysis: CV Events With Intensive- Vs Moderate-Dose Statins
Incident Diabetes Rate Highest for Atorvastatin, Rosuvastatin Vs Pravastatin Over 14 Years
Incident Diabetes Rate Greater with High- Vs Moderate- or Low-Potency Statins
Incident Diabetes Rate Highest for Atorvastatin, Rosuvastatin Vs Pravastatin for Primary and Secondary Prevention
Incident Diabetes by Statin Use: Design
ACC/AHA Cholesterol Guidelines 2013: High- and Moderate-Intensity Statin Therapy
Statin Potency New-Onset Diabetes Risk | NDEI
Statin Potency & Type 2 Diabetes Risk | NDEI
Statin Adherence Associated With Increased Type 2 Diabetes Risk | NDEI
Statin Adherence & Type 2 Diabetes Risk | NDEI
Statin Adherence & Risk for New-Onset Type 2 Diabetes | NDEI
High-Potency Statins & Increased Diabetes Risk Secondary Prevention | NDEI
GAUSS-3 Evolocumab Reduces LDL-C in Statin-Intolerant Patients | NDEI
GAUSS-3 Absolute LDL-C Reduction With Evolocumab Statin Intolerance | NDEI
GAUSS-3: LDL-C Goal Achievement With Evolocumab Statin Intolerance | NDEI
GAUSS-3 Evolocumab Effects on Lipoproteins in Statin-Intolerant Patients | NDEI
GAUSS-3 Evolocumab Use in Statin-Intolerant Patients Muscle Symptoms | NDEI
GAUSS-3 Muscle-Related Adverse Events With Evolocumab & Ezetimibe | NDEI
GAUSS-3 Design Evolocumab Vs Ezetimibe in Statin Intolerance | NDEI